ClinicalTrials.gg
CompletedNCT02595970IPSI-PSOUpdated Apr 17, 2019Results posted

Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis

A Phase 3 interventional study of Secukinumab in Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 17 sites in France. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-17.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
29th of 54
120 · median 124
Started
2015
with 6 others
Phase 3
24 of 54
none open now
Registered
24th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 29th largest by enrollment, is one of 7 that started in 2015, is one of 24 in phase 3, and was the 24th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

Evaluate psoriasis severity and its psychosocial impact using a novel Patient Reported Outcome (the Simplified Psoriasis Index SPI) at 16 weeks, as well as long-term safety, tolerability and efficacy of secukinumab administered subcutaneously during 52 weeks (plus extension) in patients with moderate to severe psoriasis.

Read the detailed description

Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis

03

Conditions studied

  • Psoriasis

Keywords

  • Psoriasis
  • Secukinumab
  • Simplified Psoriasis Index
  • CAIN457A
  • AIN457AFR01
  • AIN457A
  • Skin condition
  • skin disease
  • itching condition
  • psoriasis vulgaris
  • relapsing/remitting psoriasis
  • immune-mediated systemic disease
  • skin lesions
  • red skin lesions
  • scaly patches
  • papules
  • plaques
  • itching
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with a history of chronic, moderate to severe plaque psoriasis (PASI ≥12; BSA (body surface area) ≥10 and IGA mod 2011 (Investigator's Global Assessment) ≥3) for at least 6 months
  • patient candidates for systemic therapy.
  • .

Exclusion criteria

Exclusion Criteria:

  • previous treatment with agent targeting IL-17 (interleukine-17) or IL-17 receptor.
  • recent treatment with topical treatment (2 weeks), systemic agents (4 weeks for methotrexate, Ciclosporine A; systemic retinoids and other systemic treatment), TNF (tumor necrosis factor) inhibitors (3 months) or IL-12/23 inhibitors (6 months).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Secukinumab

    Weekly sub cutaneous injections of 300 mg during the first month and then Monthly until Week 52 plus extension until 03/11/2016.

    Drug: Secukinumab

Interventions

  • weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.

    Also known as: open label, no other intervention

06

What researchers measure

Primary outcomes

  1. proSPI (s) at Week 16 Compared to Baseline

    The primary efficacy outcome of this study evaluates the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed for the purpose of this study.

    Time frame: Week 0 (baseline) to 16 weeks

  2. Changes of saSPI (s) at Week 16 Compared to Baseline

    The primary efficacy objective of the study was to evaluate the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed. proSPI (s) score range is 0 to 50. Higher score means worse condition

    Time frame: Week 0 (baseline) to 16 weeks

Secondary outcomes

  1. PASI (Psoriasis Area Severity Index) Score

    PASI administered by a professional score range: 0 (no disease) to 72 (maximal disease)

    Time frame: week 0, 16, 52

  2. Correlation Between PASI and proSPI (s)

    Psoriasis Area Severity Index vs Professional Version of Simplified Psoraisis Index (proSPI) score

    Time frame: week 0, 16, 52

  3. proSPI (s, p and i) Over Time

    Professional Version of Simplified Psoriasis Index (proSPI) SPI for Simplified Psoriasis Index. SPI is composed of 3 domains : * s for the severity, min =0 and max=50 * p for the psychosocial, min=0 and max=10 * i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure

    Time frame: weeks 0, 16, 52

  4. saSPI (s, p and i) Over Time

    Self-administered Simplified Psoriasis Index (saSPI) SPI for Simplified Psoriasis Index. SPI is composed of 3 domains : * s for the severity, min =0 and max=50 * p for the psychosocial, min=0 and max=10 * i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure

    Time frame: weeks 0, 16, 52

  5. DLQI (Dermatology Life Quality Index) Over Time

    DLQI score has a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired MEANING OF DLQI SCORES 0 - 1 no effect on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life

    Time frame: weeks 0, 16, 52

  6. Self-administered PASI (SA-PASI)

    self-administered PASI (SA-PASI) score

    Time frame: weeks 0, 16, 52

  7. Psoriasis Symptom Diary (PSD) Score

    assessment of pain, itching and scaling using the Psoriasis Symptom Diary questionnaire over time PSD scores range from 0 to 10, with higher scores indicating a worse condition for each assessment: pain, itching and scaling

    Time frame: weeks 0, 16, 52

  8. Correlation Between proSPI (for Each Component: s, p and i) and DLQI

    Correlation between proSPI (for each component: s, p and i) and DLQI is summarized in table below

    Time frame: weeks 0, 16, 52

  9. Correlation Between proSPI (for Components p and i) and PASI

    Correlation between proSPI (p, i) and PASI score by visit (Full Analysis Set (observed)) is summarized in table below

    Time frame: Over time (from Week 0 to Week 52)

07

Results

Posted Apr 17, 2019
Limitations and caveats
The two deaths (i.e.; head injury and lymphoma) were not related to the study treatment

Participant flow

Study centers: This study involved 17 active centers who enrolled (or recruited) patients in France First patient enrolled: 20-May-2015 Last patient completed: 09-Feb-2017

Participant flow — Overall Study
MilestoneSingle Arm Secukinumab
Started120
Completed100
Not completed20
Withdrew: Withdrawal by subject2
Withdrew: Physician decision2
Withdrew: Protocol violation4
Withdrew: Adverse event5
Withdrew: Lack of efficacy7

Outcome measures

PrimaryproSPI (s) at Week 16 Compared to Baseline

The primary efficacy outcome of this study evaluates the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed for the purpose of this study.

Time frame:
Week 0 (baseline) to 16 weeks
Reported as:
Mean · scores on a scale
proSPI (s) at Week 16 Compared to Baseline
scores on a scaleSingle Arm Secukinumab
W024.89 ± 10.747
W162.34 ± 6.144
Statistical analysis
  • Single Arm Secukinumab · t-test, 2 sided · p = <0.0001 · Mean difference (net): -22.6 · 95% CI -24.52 to 20.59
SecondaryPASI (Psoriasis Area Severity Index) Score

PASI administered by a professional score range: 0 (no disease) to 72 (maximal disease)

Time frame:
week 0, 16, 52
Reported as:
Mean · scores on a scale
PASI (Psoriasis Area Severity Index) Score
scores on a scaleSingle Arm Secukinumab
W023.09 ± 10.541
W162.23 ± 3.927
W523.16 ± 5.427
SecondaryCorrelation Between PASI and proSPI (s)

Psoriasis Area Severity Index vs Professional Version of Simplified Psoraisis Index (proSPI) score

Time frame:
week 0, 16, 52
Reported as:
Number · Spearman Correlation coefficient
Correlation Between PASI and proSPI (s)
Spearman Correlation coefficientSingle Arm Secukinumab
W00.691 (0.58 to 0.78)
W160.814 (0.74 to 0.87)
W520.927 (0.89 to 0.95)
SecondaryproSPI (s, p and i) Over Time

Professional Version of Simplified Psoriasis Index (proSPI) SPI for Simplified Psoriasis Index. SPI is composed of 3 domains : * s for the severity, min =0 and max=50 * p for the psychosocial, min=0 and max=10 * i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure

Time frame:
weeks 0, 16, 52
Reported as:
Mean · scores on a scale
proSPI (s, p and i) Over Time
scores on a scaleSingle Arm Secukinumab
proSPI (s) - W024.89 ± 10.747
proSPI (s) - W161.83 ± 4.427
proSPI (s) - W522.93 ± 6.557
proSPI (p) - W07.80 ± 1.885
proSPI (p) - W161.34 ± 2.201
proSPI (p) - W521.59 ± 2.341
proSPI (i) - W04.26 ± 1.924
proSPI (i) - W164.78 ± 1.633
proSPI (i) - W524.67 ± 1.613
SecondarysaSPI (s, p and i) Over Time

Self-administered Simplified Psoriasis Index (saSPI) SPI for Simplified Psoriasis Index. SPI is composed of 3 domains : * s for the severity, min =0 and max=50 * p for the psychosocial, min=0 and max=10 * i for the intervention, min = 0 and max = 10 For each domain, high values represented a worse outcome The 3 subscales cannot be combined Please use sore on a scale for the unit of measure

Time frame:
weeks 0, 16, 52
Reported as:
Mean · saSPI score
saSPI (s, p and i) Over Time
saSPI scoreSingle Arm Secukinumab
saSPI(s) - W023.54 ± 10.412
saSPI(s) - W161.80 ± 4.319
saSPI(s) - W522.15 ± 4.229
saSPI(p) - W08.18 ± 1.855
saSPI(p) - W161.54 ± 2.299
saSPI(p) - W521.47 ± 2.126
saSPI(i) - W04.34 ± 1.940
saSPI(i) - W164.39 ± 2.221
saSPI(i) - W524.33 ± 2.276
SecondaryDLQI (Dermatology Life Quality Index) Over Time

DLQI score has a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired MEANING OF DLQI SCORES 0 - 1 no effect on patient's life 2 - 5 small effect on patient's life 6 - 10 moderate effect on patient's life 11 - 20 very large effect on patient's life 21 - 30 extremely large effect on patient's life

Time frame:
weeks 0, 16, 52
Reported as:
Mean · DLQI score (range : 0 - 30)
DLQI (Dermatology Life Quality Index) Over Time
DLQI score (range : 0 - 30)Single Arm Secukinumab
WO13.6 ± 7.44
W162.1 ± 3.67
W521.9 ± 3.37
SecondarySelf-administered PASI (SA-PASI)

self-administered PASI (SA-PASI) score

Time frame:
weeks 0, 16, 52
Reported as:
Mean · saPASI score (range: 0 to 72)
Self-administered PASI (SA-PASI)
saPASI score (range: 0 to 72)Single Arm Secukinumab
WO25.8 ± 13.55
W162.6 ± 6.66
W523.3 ± 7.10
SecondaryPsoriasis Symptom Diary (PSD) Score

assessment of pain, itching and scaling using the Psoriasis Symptom Diary questionnaire over time PSD scores range from 0 to 10, with higher scores indicating a worse condition for each assessment: pain, itching and scaling

Time frame:
weeks 0, 16, 52
Reported as:
Mean · scores on a scale
Psoriasis Symptom Diary (PSD) Score
scores on a scaleSingle Arm Secukinumab
Intensity of pain recorded in PSD- W05.2 ± 3.18
Intensity of pain recorded in PSD - W160.9 ± 2.00
Intensity of pain recorded in PSD - W520.9 ± 1.78
Intensity of itching recorded in PSD - W06.7 ± 2.85
Intensity of itching recorded in PSD - W161.3 ± 2.21
Intensity of itching recorded in PSD - W521.4 ± 2.11
Intensity of scaling recorded in PSD - W06.5 ± 2.70
Intensity of scaling recorded in PSD - W161.0 ± 1.96
Intensity of scaling recorded in PSD - W521.3 ± 2.00
SecondaryCorrelation Between proSPI (for Each Component: s, p and i) and DLQI

Correlation between proSPI (for each component: s, p and i) and DLQI is summarized in table below

Time frame:
weeks 0, 16, 52
Reported as:
Number · Spearman correlation coefficient
Correlation Between proSPI (for Each Component: s, p and i) and DLQI
Spearman correlation coefficientSingle Arm Secukinumab
proSPI (s) and DLQI - W00.224 (0.04 to 0.39)
proSPI (s) and DLQI - W160.418 (0.25 to 0.56)
proSPI (s) and DLQI - W520.514 (0.34 to 0.65)
proSPI (p) and DLQI - W00.494 (0.34 to 0.62)
proSPI (p) and DLQI - W160.671 (0.55 to 0.76)
proSPI (p) and DLQI - W520.757 (0.65 to 0.83)
proSPI (i) and DLQI - W00.102 (-0.08 to 0.28)
proSPI (i) and DLQI - W160.016 (-0.17 to 0.20)
proSPI (i) and DLQI - W520.131 (-0.08 to 0.33)
SecondaryCorrelation Between proSPI (for Components p and i) and PASI

Correlation between proSPI (p, i) and PASI score by visit (Full Analysis Set (observed)) is summarized in table below

Time frame:
Over time (from Week 0 to Week 52)
Reported as:
Number · Spearman correlation coefficient
Correlation Between proSPI (for Components p and i) and PASI
Spearman correlation coefficientSingle Arm Secukinumab
proSPI (p) and PASI - W00.173 (-0.01 to 0.34)
proSPI (p) and PASI - W160.678 (0.56 to 0.77)
proSPI (p) and PASI - W520.749 (0.64 to 0.83)
proSPI (i) and PASI - W00.014 (-0.17 to 0.19)
proSPI (i) and PASI - W160.105 (-0.08 to 0.29)
proSPI (i) and PASI - W520.172 (-0.04 to 0.36)
PrimaryChanges of saSPI (s) at Week 16 Compared to Baseline

The primary efficacy objective of the study was to evaluate the benefit of secukinumab on the severity of psoriasis based on the SPI. This index comprises 3 components: severity (SPIs), psychosocial (SPIp) and intervention (SPIi) and were evaluated by both health care professional (professional, proSPI) and the patient (self-administered: saSPI). Only the severity components were evaluated for the primary objective: proSPI (s) and saSPI (s). Changes at Week 16 compared to Baseline in patients suffering from moderate to severe plaque psoriasis were analyzed. proSPI (s) score range is 0 to 50. Higher score means worse condition

Time frame:
Week 0 (baseline) to 16 weeks
Reported as:
Mean · scores on a scale
Changes of saSPI (s) at Week 16 Compared to Baseline
scores on a scaleSingle Arm Secukinumab
W023.54 ± 10.412
W161.99 ± 4.508
Statistical analysis
  • Single Arm Secukinumab · t-test, 2 sided · p = <0.0001 · Mean difference (net): -21.6 · 95% CI -23.52 to 19.58

Adverse events

Collected over baseline to 16 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 300mg2/120 (1.7%)13/120 (10.8%)86/120 (71.7%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventAIN457 300mg
Coronary artery occlusionCardiac disorders1/120
Punctate keratitisEye disorders1/120
StomatitisGastrointestinal disorders1/120
Strangulated umbilical herniaGastrointestinal disorders1/120
Face oedemaGeneral disorders1/120
Head injuryInjury, poisoning and procedural complications1/120
Meniscus injuryInjury, poisoning and procedural complications1/120
Tendon ruptureInjury, poisoning and procedural complications1/120
Diabetes mellitusMetabolism and nutrition disorders1/120
HypoglycaemiaMetabolism and nutrition disorders1/120
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAIN457 300mg
NasopharyngitisInfections and infestations13/120
Back painMusculoskeletal and connective tissue disorders13/120
DiarrhoeaGastrointestinal disorders12/120
BronchitisInfections and infestations11/120
RhinitisInfections and infestations11/120
PsoriasisSkin and subcutaneous tissue disorders11/120
AstheniaGeneral disorders10/120
InfluenzaInfections and infestations10/120
HeadacheNervous system disorders9/120
HypertensionVascular disorders9/120

Baseline characteristics

FAS

Age, Continuous
Age, Continuous(years)Single Arm Secukinumab
Mean45.9 ± 14.17
Sex: Female, Male
Sex: Female, Male(Participants)Single Arm Secukinumab
Female37
Male83
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Single Arm Secukinumab
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander1
Black or African American1
White116
More than one race0
Unknown or Not Reported0
proSPI (s)
proSPI (s)(scores on a scale)Single Arm Secukinumab
Mean24.9 ± 10.71
saSPI (s)
saSPI (s)(score on a scale for each domain of SPI)Single Arm Secukinumab
Mean23.5 ± 10.37
08

Study locations

17 sites
  • Novartis Investigative Site
    Le Mans, Cedex 09 72037, France
  • Novartis Investigative Site
    Limoges cedex, Haute Vienne 87000, France
  • Novartis Investigative Site
    Toulon Cedex 9, Val De Marne 83800, France
  • Novartis Investigative Site
    Amiens Cedex 1, 80054, France
  • Novartis Investigative Site
    Antony, 92160, France
  • Novartis Investigative Site
    Argenteuil, 95107, France
  • Novartis Investigative Site
    Bordeaux, 33076, France
  • Novartis Investigative Site
    Brest, 29609, France
  • Novartis Investigative Site
    La Rochelle, 17019, France
  • Novartis Investigative Site
    Marseille Cedex 05, 13885, France
  • Novartis Investigative Site
    Martigues, 13500, France
  • Novartis Investigative Site
    Metz, 57077, France
  • Novartis Investigative Site
    Nice, 06202, France
  • Novartis Investigative Site
    Paris, 75014, France
  • Novartis Investigative Site
    Paris, 75877, France
  • Novartis Investigative Site
    Rouen, 76031, France
  • Novartis Investigative Site
    Toulouse Cedex, 31400, France
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2015 to primary completion in Feb 2017, 20 months.

Results were first posted in Apr 2019, 2 years 2 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 20 months is above that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2015
First posted
Nov 4, 2015
StartActual
May 20, 2015
Primary completionActual
Feb 9, 2017
CompletionActual
Feb 9, 2017
Results first posted
Apr 17, 2019
Last update
Apr 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02595970
Responsible party
Sponsor
First posted
Nov 4, 2015
Start date
May 20, 2015
Primary completion
Feb 9, 2017
Completion
Feb 9, 2017
Results posted
Apr 17, 2019
Last update
Apr 17, 2019

Study contacts

PHILIPPE CELERIER
principal investigator · HOPITAL SAINT LOUIS - LA ROCHELLE
MARIE-ALETH RICHARD
principal investigator · HOPITAL TIMONES - MARSEILLE
SELIM ARACTINGI
principal investigator · HOPITAL COCHIN - PARIS
PIERRE ANDRE BECHEREL
principal investigator · HOPITAL PRIVE D'ANTONY - ANTONY
EMMANUEL MAHE
principal investigator · CH VICTOR DUPOUY - ARGENTEUIL
PHILIPPE LACOUR
principal investigator · HOPITAL L'ARCHET - NICE
MIREILLE RUER MULARD
principal investigator · CABINET BATEAU BLANC - MARTIGUES
THIERRY BOYE
principal investigator · HIA SAINTE ANNE - TOULON
ANNE DUVAL-MODESTE
principal investigator · HOPITAL CHARLES NICOLLE - ROUEN
MARIE BEYLOT-BARRY
principal investigator · HOPITAL SAINT ANDRE - BORDEAUX
LAURENT MISERY
principal investigator · HOPITAL MORVAN - BREST
VINCENT DESCAMPS
principal investigator · HOPITAL BICHAT CLAUDE BERNARD - PARIS
GUILLAUME CHABY
principal investigator · CHU AMIENS NORD - AMIENS
CARLE PAUL
principal investigator · HOPITAL LARREY - TOULOUSE
CHRISTOPHE BEDANE
principal investigator · HOPITAL DUPUYTREN - LIMOGES
HERVÉ MAILLARD
principal investigator · CENTRE HOSPITALIER LE MANS - LE MANS
JEAN-FRANCOIS CUNY
principal investigator · HIA LEGOUEST - METZ

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion